Sector Gamma AS Sells 17,851 Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Sector Gamma AS lowered its holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 11.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 141,218 shares of the medical equipment provider’s stock after selling 17,851 shares during the quarter. Zimmer Biomet comprises about 4.2% of Sector Gamma AS’s investment portfolio, making the stock its 9th largest position. Sector Gamma AS’s holdings in Zimmer Biomet were worth $17,186,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently bought and sold shares of the business. PFG Advisors boosted its stake in Zimmer Biomet by 4.6% in the fourth quarter. PFG Advisors now owns 1,899 shares of the medical equipment provider’s stock worth $231,000 after purchasing an additional 84 shares in the last quarter. Quent Capital LLC boosted its stake in Zimmer Biomet by 21.6% in the fourth quarter. Quent Capital LLC now owns 518 shares of the medical equipment provider’s stock worth $63,000 after purchasing an additional 92 shares in the last quarter. Pinnacle Associates Ltd. boosted its stake in Zimmer Biomet by 5.0% in the third quarter. Pinnacle Associates Ltd. now owns 2,020 shares of the medical equipment provider’s stock worth $227,000 after purchasing an additional 97 shares in the last quarter. Financial Advocates Investment Management boosted its stake in Zimmer Biomet by 3.8% in the third quarter. Financial Advocates Investment Management now owns 2,625 shares of the medical equipment provider’s stock worth $295,000 after purchasing an additional 97 shares in the last quarter. Finally, Stokes Family Office LLC boosted its stake in Zimmer Biomet by 4.1% in the third quarter. Stokes Family Office LLC now owns 2,498 shares of the medical equipment provider’s stock worth $280,000 after purchasing an additional 99 shares in the last quarter. Institutional investors and hedge funds own 88.89% of the company’s stock.

Zimmer Biomet Stock Down 0.3 %

Shares of ZBH stock traded down $0.40 on Friday, hitting $119.35. 1,099,241 shares of the stock were exchanged, compared to its average volume of 1,046,552. The company has a current ratio of 1.61, a quick ratio of 0.78 and a debt-to-equity ratio of 0.39. The firm has a market capitalization of $24.52 billion, a P/E ratio of 24.41, a price-to-earnings-growth ratio of 2.20 and a beta of 1.01. The business has a 50-day moving average of $125.98 and a 200 day moving average of $119.52. Zimmer Biomet Holdings, Inc. has a fifty-two week low of $102.00 and a fifty-two week high of $149.25.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings data on Thursday, February 8th. The medical equipment provider reported $2.20 EPS for the quarter, topping analysts’ consensus estimates of $2.15 by $0.05. Zimmer Biomet had a return on equity of 12.79% and a net margin of 13.85%. The firm had revenue of $1.94 billion for the quarter, compared to analyst estimates of $1.93 billion. During the same quarter last year, the company earned $1.88 EPS. The company’s revenue was up 6.3% on a year-over-year basis. Equities analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.07 EPS for the current year.

Zimmer Biomet Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, April 30th. Shareholders of record on Friday, March 29th will be issued a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.80%. The ex-dividend date of this dividend is Wednesday, March 27th. Zimmer Biomet’s dividend payout ratio is presently 19.63%.

Insider Buying and Selling at Zimmer Biomet

In related news, VP Chad F. Phipps sold 26,156 shares of the firm’s stock in a transaction on Thursday, February 22nd. The stock was sold at an average price of $128.62, for a total transaction of $3,364,184.72. Following the sale, the vice president now owns 44,145 shares of the company’s stock, valued at approximately $5,677,929.90. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Company insiders own 0.95% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on ZBH shares. Barclays boosted their target price on Zimmer Biomet from $120.00 to $130.00 and gave the stock an “underweight” rating in a research report on Monday, February 12th. TheStreet upgraded Zimmer Biomet from a “c” rating to a “b-” rating in a research report on Thursday, February 8th. Royal Bank of Canada restated an “outperform” rating and set a $140.00 target price on shares of Zimmer Biomet in a research report on Friday, February 9th. Raymond James boosted their target price on Zimmer Biomet from $133.00 to $137.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 3rd. Finally, JPMorgan Chase & Co. boosted their target price on Zimmer Biomet from $115.00 to $125.00 and gave the stock a “neutral” rating in a research report on Friday, February 9th. One analyst has rated the stock with a sell rating, nine have assigned a hold rating and six have given a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $139.39.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.